Medigene and Epimab to codevelop TCR-guided T-cell engagers
Feb. 27, 2025
Medigene AG and Epimab Biotherapeutics Inc. have entered a strategic codevelopment agreement to research and develop off-the-shelf T-cell receptor (TCR)-guided T-cell engagers (TCR-TCEs) for the treatment of immune-related disorders, such as solid tumors.